Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Complex Pandemic Accord negotiations have been underway since 2021, with 13 formal meetings and numerous informal sessions.

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...